Clinical Trial Update: Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating prophylaxis of post-TIPS hepatic encephalopathy using rifaximin and lactulose is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatic Encephalopathy
• Liver Disease
• Portal Hypertension

Drugs mentioned

• LACTULOSE (Lactulose)
• Rifaximin (rifaximin)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Hepatic Encephalopathy, Cirrhosis, Liver | Phase 4 | Status: RECRUITING